BMY:NYE-Bristol-Myers Squibb Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 49.82

Change

+0.88 (+1.80)%

Market Cap

USD 100.17B

Volume

0.01B

Analyst Target

USD 73.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-22 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
LLY Eli Lilly and Company

+9.52 (+1.16%)

USD 657.70B
JNJ Johnson & Johnson

+0.83 (+0.53%)

USD 365.65B
ABBV AbbVie Inc

+3.62 (+2.13%)

USD 306.02B
NVO Novo Nordisk A/S

+1.58 (+2.71%)

USD 281.29B
PFE Pfizer Inc

+0.49 (+2.22%)

USD 124.26B
OGN Organon & Co

+0.61 (+5.74%)

USD 2.88B
GSK GlaxoSmithKline PLC ADR

+0.18 (+0.49%)

N/A
MRK Merck & Company Inc

+1.12 (+1.44%)

N/A
NVS Novartis AG ADR

+0.87 (+0.79%)

N/A

ETFs Containing BMY

GF0F:XETRA 7.49 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.55 % 0.00 %

+0.02 (+0.00%)

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 4.49 % 0.00 %

+0.04 (+0.00%)

N/A
KNGU:CA Brompton U.S. Cash Flow K.. 4.20 % 0.00 %

-0.14 (0.00%)

CAD 0.01B
MEDX Horizon Kinetics Medical .. 4.15 % 0.00 %

+0.44 (+0.00%)

N/A
CAMX Cambiar Aggressive Value .. 3.89 % 0.00 %

+0.53 (+0.00%)

USD 0.05B
DIVP The Advisors’ Inner .. 3.84 % 0.00 %

+0.34 (+0.00%)

USD 0.02B
XUDV Franklin Templeton ETF Tr.. 3.68 % 0.00 %

+0.57 (+0.00%)

N/A
ZYUS:AU ANZ S&P 500 High Yield Lo.. 3.07 % 0.00 %

-0.23 (0.00%)

USD 0.08B
MVFD Northern Lights Fund Trus.. 3.00 % 0.00 %

+0.55 (+0.00%)

USD 0.07B
MVUS:PA 3.00 % 0.00 %

N/A

N/A
SPMV:PA 3.00 % 0.00 %

N/A

N/A
MHOT:AU VanEck Morningstar Wide M.. 2.98 % 0.00 %

-0.57 (0.00%)

N/A
MOAT:AU VanEck Morningstar Wide M.. 2.97 % 0.00 %

-2.77 (0.00%)

USD 1.04B
CDNA:CA 2.94 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 2.82 % 0.00 %

+0.16 (+0.00%)

USD 0.02B
ABFL Abacus FCF Leaders ETF 2.78 % 0.00 %

+1.41 (+0.00%)

N/A
HEAL:CA 2.66 % 0.00 %

N/A

N/A
DHS:SW 2.39 % 0.00 %

N/A

N/A
DHSA:SW WisdomTree US Equity Inco.. 2.39 % 0.00 %

N/A

N/A
TDIV:PA VanEck Morningstar Develo.. 2.34 % 0.00 %

N/A

USD 1.63B
TDIV:SW VanEck Morningstar Develo.. 2.26 % 0.00 %

-0.02 (0.00%)

USD 1.91B
XDGI:XETRA Xtrackers MSCI Global SDG.. 2.25 % 0.00 %

+0.10 (+0.00%)

N/A
VALQ American Century STOXX U... 2.21 % 0.29 %

+1.27 (+0.00%)

USD 0.22B
INCM:AU BetaShares Global Income .. 2.16 % 0.00 %

-0.13 (0.00%)

USD 0.03B
INVN The Alger ETF Trust 2.14 % 0.00 %

+0.37 (+0.00%)

N/A
HEAL:SW iShares Healthcare Innova.. 2.10 % 0.00 %

N/A

USD 1.05B
2B78:XETRA iShares Healthcare Innova.. 1.97 % 0.00 %

+0.02 (+0.00%)

USD 1.05B
ZUH:CA BMO Equal Weight US Healt.. 1.89 % 0.39 %

+1.70 (+0.00%)

CAD 0.21B
PUD.B:CA 1.82 % 0.66 %

N/A

N/A
DIVG Invesco Exchange-Traded F.. 1.79 % 0.00 %

+0.65 (+0.00%)

USD 3.32M
UVDV 1.72 % 0.00 %

N/A

N/A
JAVA JPMorgan Active Value ETF 1.57 % 0.00 %

+1.28 (+0.00%)

USD 3.01B
UC82:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

-2.50 (0.00%)

USD 0.03B
UC86:LSE UBS(Lux)Fund Solutions .. 1.35 % 0.00 %

-0.01 (0.00%)

USD 0.25B
SPXB 1.32 % 0.15 %

N/A

N/A
ITEK:PA HAN-GINS Tech Megatrend E.. 0.95 % 0.00 %

+0.11 (+0.00%)

N/A
UC98:LSE UBS(Lux)Fund Solutions .. 0.74 % 0.00 %

-15.50 (0.00%)

USD 0.12B
BSUS:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

-4.80 (0.00%)

N/A
UC97:LSE UBS(Lux)Fund Solutions .. 0.72 % 0.00 %

-0.08 (0.00%)

USD 0.12B
UET0:F UBS (Lux) Fund Solutions .. 0.65 % 0.00 %

-0.05 (0.00%)

N/A
UET0:XETRA UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.07 (0.00%)

N/A
CBSUST:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.06 (0.00%)

N/A
CBSUS:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

-0.07 (0.00%)

N/A
CBSUSE:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
CBSUSH:SW UBS(Lux)Fund Solutions .. 0.65 % 0.00 %

N/A

N/A
QUIG:CA Mackenzie US Investment G.. 0.62 % 0.28 %

-0.76 (0.00%)

CAD 0.52B
UC76:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

-0.09 (0.00%)

USD 0.07B
UC85:LSE UBS Barclays US Liquid Co.. 0.53 % 0.00 %

-7.00 (0.00%)

USD 0.12B
CNCR Loncar Cancer Immunothera.. 0.00 % 0.79 %

+0.40 (+0.00%)

USD 8.35M
DHS WisdomTree U.S. High Divi.. 0.00 % 0.38 %

+1.82 (+0.00%)

N/A
GBF iShares Government/Credit.. 0.00 % 0.20 %

+0.12 (+0.00%)

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

+0.92 (+0.00%)

N/A
JHMH 0.00 % 0.46 %

N/A

N/A
ONEV SPDR® Russell 1000 Low V.. 0.00 % 0.20 %

+2.72 (+0.00%)

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

+0.24 (+0.00%)

N/A
QLTA iShares Aaa - A Rated Cor.. 0.00 % 0.15 %

+0.07 (+0.00%)

USD 1.63B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

+0.03 (+0.00%)

USD 0.40B
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

+0.50 (+0.00%)

USD 0.02B
HONR 0.00 % 0.65 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.03 (+0.00%)

CAD 0.01B
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

+0.19 (+0.00%)

N/A
HUL-U:CA 0.00 % 0.00 %

N/A

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.77 %

-0.46 (0.00%)

N/A
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

-0.46 (0.00%)

N/A
SICK 0.00 % 0.95 %

N/A

N/A
UXM.B:CA 0.00 % 0.67 %

N/A

N/A
HUL:CA 0.00 % 2.20 %

N/A

N/A
BVAL 0.00 % 0.65 %

N/A

N/A
DHS:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-13.60 (0.00%)

N/A
DHSA:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

+0.11 (+0.00%)

N/A
DHSD:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

+0.04 (+0.00%)

N/A
DHSG:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

+5.50 (+0.00%)

N/A
DHSP:LSE WisdomTree US Equity Inco.. 0.00 % 0.00 %

-16.50 (0.00%)

N/A
LUMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-315.00 (0.00%)

N/A
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

-16.50 (0.00%)

USD 0.07B
USMV:LSE Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-1.20 (0.00%)

USD 9.87M
OSX2:F Ossiam Lux - Ossiam US Mi.. 0.00 % 0.00 %

-4.75 (0.00%)

N/A
T3KE:F HANetf ICAV - HAN-GINS Te.. 0.00 % 0.00 %

+0.09 (+0.00%)

USD 0.10B
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 0.00 % 0.00 %

N/A

USD 0.13B
OSX2:XETRA Ossiam US Minimum Varianc.. 0.00 % 0.00 %

-3.55 (0.00%)

N/A
VDIV:XETRA VanEck Morningstar Develo.. 0.00 % 0.00 %

+0.19 (+0.00%)

N/A
VMUS:XETRA 0.00 % 0.00 %

N/A

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A
ELLE:LSE Amundi Global Gender Equa.. 0.00 % 0.00 %

+0.20 (+0.00%)

USD 0.05B
REVS Columbia Research Enhance.. 0.00 % 0.00 %

+0.29 (+0.00%)

USD 0.06B
JEPI JPMorgan Equity Premium I.. 0.00 % 0.00 %

+1.12 (+0.00%)

USD 36.19B
HHL-B:CA Harvest Healthcare Leader.. 0.00 % 0.00 %

N/A

N/A
AGNG Global X Aging Population.. 0.00 % 0.00 %

+0.57 (+0.00%)

USD 0.05B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

+0.25 (+0.00%)

CAD 0.08B
DAVV:F VanEck Crypto and Blockch.. 0.00 % 0.00 %

-0.19 (0.00%)

N/A
DAVV:XETRA VanEck Crypto and Blockch.. 0.00 % 0.00 %

+0.51 (+0.00%)

N/A
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.92% 50% F 28% F
Dividend Return 2.19% 90% A- 83% B
Total Return -9.72% 50% F 33% F
Trailing 12 Months  
Capital Gain 1.69% 60% D- 60% D-
Dividend Return 4.98% 80% B- 72% C
Total Return 6.67% 70% C- 68% D+
Trailing 5 Years  
Capital Gain -18.26% 22% F 19% F
Dividend Return 17.95% 44% F 46% F
Total Return -0.31% 22% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain -2.33% 30% F 24% F
Dividend Return 0.96% 30% F 28% F
Total Return 3.29% 60% D- 66% D+
Risk Return Profile  
Volatility (Standard Deviation) 19.41% 50% F 53% F
Risk Adjusted Return 4.95% 30% F 25% F
Market Capitalization 100.17B 29% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.